Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm?
作者信息
Oelschlaeger Peter, Ai Ni, Duprez Kevin T, Welsh William J, Toney Jeffrey H
机构信息
Chemistry Department and Center for Macromolecular Modeling and Materials Design, California State Polytechnic University, Pomona, California, USA.
出版信息
J Med Chem. 2010 Apr 22;53(8):3013-27. doi: 10.1021/jm9012938.
Abstract
摘要
相似文献
1
Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm?不断演变的碳青霉烯酶：药物化学家能否在即将到来的风暴之前先行一步？
J Med Chem. 2010 Apr 22;53(8):3013-27. doi: 10.1021/jm9012938.
2
Crystal structures of KPC-2 β-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226.KPC-2 β-内酰胺酶与 3-硝基苯硼酸和 penam 砜 PSR-3-226 复合物的晶体结构。
Antimicrob Agents Chemother. 2012 May;56(5):2713-8. doi: 10.1128/AAC.06099-11. Epub 2012 Feb 13.
3
Local interactions with the Glu166 base and the conformation of an active site loop play key roles in carbapenem hydrolysis by the KPC-2 β-lactamase.局部与 Glu166 碱基相互作用以及活性位点环的构象在 KPC-2 β-内酰胺酶催化碳青霉烯水解中起关键作用。
J Biol Chem. 2021 Jan-Jun;296:100799. doi: 10.1016/j.jbc.2021.100799. Epub 2021 May 20.
4
Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.碳青霉烯酶 2（KPC-2），在 Ambler 位置 Asp179 的取代以及对头孢他啶-阿维巴坦的耐药性：β-内酰胺酶蛋白质工程产生独特的抗生素耐药表型。
mBio. 2017 Oct 31;8(5):e00528-17. doi: 10.1128/mBio.00528-17.
5
KPC-2 β-lactamase enables carbapenem antibiotic resistance through fast deacylation of the covalent intermediate.KPC-2 β-内酰胺酶通过快速脱去共价中间体的酰基而使碳青霉烯类抗生素产生耐药性。
J Biol Chem. 2021 Jan-Jun;296:100155. doi: 10.1074/jbc.RA120.015050. Epub 2020 Dec 10.
6
Structural and biochemical characterization of VIM-26 shows that Leu224 has implications for the substrate specificity of VIM metallo-β-lactamases.VIM-26的结构和生化特性表明，亮氨酸224对VIM金属β-内酰胺酶的底物特异性有影响。
FEBS J. 2015 Mar;282(6):1031-42. doi: 10.1111/febs.13200. Epub 2015 Feb 6.
7
Plasmid-mediated carbapenem-hydrolysing OXA-48 beta-lactamase in Klebsiella pneumoniae from Tunisia.突尼斯肺炎克雷伯菌中质粒介导的碳青霉烯水解OXA-48β-内酰胺酶
Int J Antimicrob Agents. 2010 Jul;36(1):91-3. doi: 10.1016/j.ijantimicag.2010.02.014. Epub 2010 Mar 30.
8
Plasmid-mediated carbapenem-hydrolysing β-lactamase KPC-2 in a Klebsiella pneumoniae isolate from Switzerland.瑞士一株肺炎克雷伯菌分离株中质粒介导的碳青霉烯水解β-内酰胺酶KPC-2
J Antimicrob Chemother. 2011 Mar;66(3):675-6. doi: 10.1093/jac/dkq499. Epub 2010 Dec 29.
9
Carbapenem-hydrolyzing oxacillinase-48 and oxacillinase-181 in Canada, 2011.2011年加拿大的碳青霉烯水解性苯唑西林酶-48和苯唑西林酶-181
Emerg Infect Dis. 2013 Jan;19(1):157-60. doi: 10.3201/eid1901.120706.
10
Ten Years with New Delhi Metallo-β-lactamase-1 (NDM-1): From Structural Insights to Inhibitor Design.与新德里金属β-内酰胺酶-1（NDM-1）共处的十年：从结构洞察到抑制剂设计
ACS Infect Dis. 2019 Jan 11;5(1):9-34. doi: 10.1021/acsinfecdis.8b00247. Epub 2018 Nov 28.
引用本文的文献
1
In Vitro Activity of "Old" and "New" Antimicrobials against the Complex.“旧”抗菌药物与“新”抗菌药物对该菌属的体外活性
Antibiotics (Basel). 2024 Jan 26;13(2):126. doi: 10.3390/antibiotics13020126.
2
Strategies to Name Metallo-β-Lactamases and Number Their Amino Acid Residues.金属β-内酰胺酶的命名策略及其氨基酸残基编号方法
Antibiotics (Basel). 2023 Dec 16;12(12):1746. doi: 10.3390/antibiotics12121746.
3
The role of adjuvants in overcoming antibacterial resistance due to enzymatic drug modification.佐剂在克服因酶促药物修饰导致的抗菌耐药性方面的作用。
RSC Med Chem. 2022 Sep 22;13(11):1276-1299. doi: 10.1039/d2md00263a. eCollection 2022 Nov 16.
4
On drug discovery against infectious diseases and academic medicinal chemistry contributions.关于抗传染病药物研发及学术药物化学的贡献。
Beilstein J Org Chem. 2022 Sep 29;18:1355-1378. doi: 10.3762/bjoc.18.141. eCollection 2022.
5
Detection and Characterization of VIM-52, a New Variant of VIM-1 from a Klebsiella pneumoniae Clinical Isolate.检测和特征分析肺炎克雷伯菌临床分离株中的 VIM-52，一种新型 VIM-1 变体。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0266020. doi: 10.1128/AAC.02660-20. Epub 2021 Aug 9.
6
Mutation S115T in IMP-Type Metallo-β-Lactamases Compensates for Decreased Expression Levels Caused by Mutation S119G.IMP 型金属β-内酰胺酶中的 S115T 突变补偿了 S119G 突变导致的表达水平降低。
Biomolecules. 2019 Nov 11;9(11):724. doi: 10.3390/biom9110724.
7
Defining the architecture of KPC-2 Carbapenemase: identifying allosteric networks to fight antibiotics resistance.定义 KPC-2 碳青霉烯酶的结构：识别变构网络以对抗抗生素耐药性。
Sci Rep. 2018 Aug 27;8(1):12916. doi: 10.1038/s41598-018-31176-0.
8
Virtual Screening and Experimental Testing of B1 Metallo-β-lactamase Inhibitors.虚拟筛选和 B1 型金属β-内酰胺酶抑制剂的实验测试。
J Chem Inf Model. 2018 Sep 24;58(9):1902-1914. doi: 10.1021/acs.jcim.8b00133. Epub 2018 Aug 29.
9
Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase Inhibitors.金属β-内酰胺酶的多样性和增殖：呼吁开发临床上有效的金属β-内酰胺酶抑制剂。
Appl Environ Microbiol. 2018 Aug 31;84(18). doi: 10.1128/AEM.00698-18. Print 2018 Sep 15.
10
Carbamylmethyl Mercaptoacetate Thioether: A Novel Scaffold for the Development of L1 Metallo-β-lactamase Inhibitors.氨基甲酰甲基巯基乙酸硫醚：一种用于开发L1金属β-内酰胺酶抑制剂的新型骨架。
ACS Med Chem Lett. 2017 Apr 24;8(5):527-532. doi: 10.1021/acsmedchemlett.7b00058. eCollection 2017 May 11.
本文引用的文献
1
Functional characterization of the antibiotic resistance reservoir in the human microflora.人体微生物群中抗生素耐药性储存库的功能特征
Science. 2009 Aug 28;325(5944):1128-1131. doi: 10.1126/science.1176950.
2
Antibiotics for emerging pathogens.针对新出现病原体的抗生素。
Science. 2009 Aug 28;325(5944):1089-93. doi: 10.1126/science.1176667.
3
The changing epidemiology of resistance.耐药性不断变化的流行病学。
J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i3-10. doi: 10.1093/jac/dkp256.
4
Has the era of untreatable infections arrived?无法治愈的感染时代已经来临了吗？
J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i29-36. doi: 10.1093/jac/dkp255.
5
Metallo-beta-lactamase inhibitory activity of phthalic acid derivatives.邻苯二甲酸衍生物的金属β-内酰胺酶抑制活性
Bioorg Med Chem Lett. 2009 Sep 1;19(17):5162-5. doi: 10.1016/j.bmcl.2009.07.018. Epub 2009 Jul 9.
6
Docking for fragment inhibitors of AmpC beta-lactamase.AmpC β-内酰胺酶片段抑制剂的对接
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7455-60. doi: 10.1073/pnas.0813029106. Epub 2009 Apr 22.
7
Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.多利培南一水合物，一种广谱碳青霉烯类抗生素。
Clin Ther. 2009 Jan;31(1):42-63. doi: 10.1016/j.clinthera.2009.01.013.
8
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.对波多黎各医疗中心医院耐碳青霉烯类铜绿假单胞菌分离株的监测：KPC和IMP-18β-内酰胺酶的传播情况
Antimicrob Agents Chemother. 2009 Apr;53(4):1660-4. doi: 10.1128/AAC.01172-08. Epub 2009 Feb 2.
9
Global resistance trends and the potential impact on empirical therapy.全球耐药趋势及其对经验性治疗的潜在影响。
Int J Antimicrob Agents. 2008 Dec;32 Suppl 4:S201-6. doi: 10.1016/S0924-8579(09)70003-2.
10
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections.多重耐药鲍曼不动杆菌感染的当前控制与治疗
Lancet Infect Dis. 2008 Dec;8(12):751-62. doi: 10.1016/S1473-3099(08)70279-2.
Zotero 插件